AMRX - Latest News

Amneal Pharmaceuticals, Inc. (AMRX), operates in Healthcare / Drug Manufacturers - Specialty & Generic, trades on NASDAQ.

Market capitalization stands near $6.04B. Trailing twelve-month P/E ratio is 38.34. Beta to the broader market is 1.22.

The article list below shows the most recent AMRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent AMRX Headlines

Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)

defenseworld.net - Oct 13, 2026

Amneal Pharmaceuticals (NASDAQ: AMRX - Get Free Report) and Neurocrine Biosciences (NASDAQ: NBIX - Get Free Report) are both healthcare companies, but

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

fool.com - Oct 10, 2026

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.

Amneal to Report Third Quarter 2026 Results on November 3, 2026

globenewswire.com - Oct 8, 2026

BRIDGEWATER, N. J.

A Look at Amneal Pharmaceuticals Inc (AMRX) After 3.7% Gain -- GF Value $8.19 vs Price $20.50

gurufocus.com - Sep 28, 2026

On September 28, 2026, Amneal Pharmaceuticals Inc (AMRX) shares rose 3. 7% to $20.

Amneal Announces FDA Approval and Launch of Lanreotide Injection

globenewswire.com - Sep 18, 2026

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production

How News Affects AMRX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track AMRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked AMRX news questions

What is the latest AMRX news headline?

The most recent AMRX headline (Oct 13, 2026) is "Head-To-Head Contrast: Neurocrine Biosciences (NASDAQ:NBIX) vs. Amneal Pharmaceuticals (NASDAQ:AMRX)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the AMRX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What AMRX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual AMRX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.